Esperion Therapeutics, Inc. [ESPR] to Ring The NASDAQ Stock Market Opening Bell
July 16 2013 - 10:00AM
ADVISORY, July 16, 2013 (GLOBE NEWSWIRE) --
What:
Esperion Therapeutics, Inc. [ESPR], a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, will
visit the NASDAQ MarketSite in Times Square in celebration of its
recent IPO and its return to the NASDAQ Stock Market as a publicly
traded company which occurred on June 26.
In honor of the occasion, Tim Mayleben, CEO &
President and Roger Newton, Executive Chairman and
CSO will ring the Opening Bell.
Where:
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Wednesday, July 17, 2013 – 9:15 a.m. to 9:30 a.m. ET
Media Contact:
Denise Powell BrewLife (510) 703-9491 dpowell@brewlife.com
NASDAQ MarketSite:
Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Facebook and Twitter:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at: http://www.facebook.com/NASDAQ.
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaqomx.
Webcast:
A live webcast of the NASDAQ Opening Bell will be available at:
http://www.nasdaq.com/about/marketsitetowervideo.asx.
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on
the market open of your choice.
About Esperion Therapeutics, Inc.
[ESPR]:
Esperion Therapeutics, Inc. is a biopharmaceutical company
focused on the research, development and commercialization of
therapies for the treatment of patients with elevated levels of
low-density lipoprotein cholesterol (LDL-C) and other
cardiometabolic risk factors. ETC-1002, Esperion's lead product
candidate, is a unique, first-in-class, orally available,
once-daily LDL-C lowering small molecule therapy designed to lower
levels of LDL-C and to avoid many of the side effects associated
with existing LDL-C lowering therapies. ETC-1002 is initially
targeted for statin intolerant patients with elevated levels of
LDL-C. For more information, please visit www.esperion.com.
About NASDAQ OMX Group:
The inventor of the electronic exchange, The NASDAQ OMX Group,
Inc., fuels economies and provides transformative technologies for
the entire lifecycle of a trade - from risk management to trade to
surveillance to clearing. In the U.S. and Europe, we own and
operate 26 markets including 3 clearinghouses and 5 central
securities depositories supporting equities, options, fixed income,
derivatives, commodities, futures and structured products. Able to
process more than 1 million messages per second at sub-55
microsecond average speeds with 99.99% uptime, our technology
drives more than 70 marketplaces in 50 developed and emerging
countries into the future, powering 1 in 10 of the world's
securities transactions. Our award-winning data products and
worldwide indexes are the benchmarks in the financial industry.
Home to approximately 3,300 listed companies worth $6 trillion in
market cap whose innovations shape our world, we give the ideas of
tomorrow access to capital today. Welcome to where the world takes
a big leap forward, daily. Welcome to the NASDAQ OMX Century. To
learn more, visit www.nasdaqomx.com. Follow us on Facebook
(http://www.facebook.com/NASDAQ) and Twitter
(http://www.twitter.com/nasdaqomx). (Symbol: NDAQ and member of
S&P 500)
-NDAQA-
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024